{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:55:15Z","timestamp":1791381315862,"version":"4.3.3"},"reference-count":17,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"id":[{"id":"https:\/\/ror.org\/05xsppr58","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Background: Chronic venous disease and lymphoedema frequently coexist, leading to significant symptom burden and impaired quality of life (QoL). Phlebotonic agents, such as diosmin, Ruscus aculeatus, Melilotus officinalis and Vitis vinifera, have demonstrated complementary anti-inflammatory, venotonic and lymphokinetic effects. However, real-world evidence on their combined use remains limited.\n\nMethods: The VIVEMA Stasis study was a retrospective observational analysis conducted in a real-world clinical setting. Adult patients with lower limb venous and\/ or lymphatic oedema received a 30-day treatment with a standardized formulation containing diosmin, R. aculeatus, M. officinalis and V. vinifera extracts, in addition to compression therapy. The primary endpoint was improvement in health-related QoL, assessed using the CIVIQ-14 questionnaire. Secondary endpoints included changes in symptom burden and limb circumference measurements.\n\nResults: Fifty-one patients (mean age 54.0 years; 84.3% female) were included. After 30 days, significant improvements were observed in QoL (global CIVIQ-14 score: p&lt;0.001), with reductions in pain, sleep disturbance and functional limitations. Objective measurements showed significant reductions in both ankle and calf circumferences (median reduction: 0.40 cm and 0.50 cm, respectively; p&lt;0.001). Symptom burden scores improved significantly (median increase from 19.0 to 25.0; p=0.002), especially for swelling, heaviness and fatigue. No adverse events were reported.\n\nConclusion: In this real-world setting, a short-term integrative treatment with a phlebotonic formulation combining diosmin, R. aculeatus, M. officinalis and V. vinifera significantly improved QoL, symptom burden and oedema in patients with chronic venous and lymphatic disease. These findings support the therapeutic potential of combined phlebotonic therapy alongside standard care.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-real-world-effectiveness-of-a-phlebotonic-formulation-combining-diosmin-ruscus-melilotus-and-vitis-vinifera-on-symptoms-and-quality-of-life-in-patients-with-chronic-venous-an<\/jats:p>","DOI":"10.7573\/dic.2025-10-1","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:23:13Z","timestamp":1770646993000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness of a phlebotonic formulation combining diosmin, Ruscus, Melilotus and Vitis vinifera on symptoms and quality of life in patients with chronic venous and lymphatic disease: results from the VIVEMA Stasis observational study"],"prefix":"10.7573","author":[{"given":"Giampiero","family":"Avruscio","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04bhk6583","id-type":"ROR","asserted-by":"publisher"}],"name":"Azienda Ospedale - Universit\u00e0 Padova"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Tirrito","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04bhk6583","id-type":"ROR","asserted-by":"publisher"}],"name":"Azienda Ospedale - Universit\u00e0 Padova"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Ragazzo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04bhk6583","id-type":"ROR","asserted-by":"publisher"}],"name":"Azienda Ospedale - Universit\u00e0 Padova"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mangrella","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xsppr58","id-type":"ROR","asserted-by":"publisher"}],"name":"Italfarmaco (Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Piazza","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xsppr58","id-type":"ROR","asserted-by":"publisher"}],"name":"Italfarmaco (Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Tanasi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xsppr58","id-type":"ROR","asserted-by":"publisher"}],"name":"Italfarmaco (Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tOrtega MA, Fraile-Mart\u00ednez O, Garc\u00eda-Montero C, et al. Understanding chronic venous disease: a critical overview of its pathophysiology and medical management. J Clin Med. 2021;10:3239. https:\/\/doi.org\/10.3390\/ jcm10153239","DOI":"10.3390\/jcm10153239"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tLohr JM, Bush RL. Venous disease in women: epidemiology, manifestations, and treatment. J Vasc Surg. 2013;57:37S\u201345S. https:\/\/doi.org\/10.1016\/j.jvs.2012.10.121","DOI":"10.1016\/j.jvs.2012.10.121"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tDe Maeseneer MG, Kakkos SK, Aherne T, et al. Editor\u2019s choice \u2013 European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs. Eur J Vasc Endovasc Surg. 2022;63:184\u2013267. https:\/\/doi.org\/10.1016\/j.ejvs.2021.12.024","DOI":"10.1016\/j.ejvs.2022.06.022"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tCazaubon M, Benigni JP, Steinbruch M, Jabbour V, Gouhier-Kodas C. Is there a difference in the clinical efficacy of diosmin and micronized purified flavonoid fraction for the treatment of chronic venous disorders? Review of available evidence. Vasc Health Risk Manag. 2021;17:591\u2013600. https:\/\/doi.org\/10.2147\/VHRM.S324112","DOI":"10.2147\/VHRM.S324112"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tO\u2019Donnell TF Jr, Passman MA, Marston WA, et al. Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery\u00ae and the American Venous Forum. J Vasc Surg. 2014;60:3S\u201359S. https:\/\/ doi.org\/10.1016\/j.jvs.2014.04.049","DOI":"10.1016\/j.jvs.2014.04.049"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tTorgbenu E, Luckett T, Buhagiar MA, Phillips JL. Guidelines relevant to diagnosis, assessment, and management of lymphedema: a systematic review. Adv Wound Care. 2023;12:15\u201327. https:\/\/doi.org\/10.1089\/wound.2021.0149","DOI":"10.1089\/wound.2021.0149"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tAnzai LM, Chang DW. Educational review: management of lymphedema-approaches, evidence for surgical and nonsurgical interventions. Ann Surg Oncol. 2025;32:6620\u20136628. https:\/\/doi.org\/10.1245\/s10434-025-17463-x","DOI":"10.1245\/s10434-025-17463-x"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tRaju S, Furrh JB 4th, Negl\u00e9n P. Diagnosis and treatment of venous lymphedema. J Vasc Surg. 2012;55:141\u2013149. https:\/\/doi.org\/10.1016\/j.jvs.2011.07.078","DOI":"10.1016\/j.jvs.2011.07.078"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tStolldorf DP, Dietrich MS, Ridner SH. A comparison of the quality of life in patients with primary and secondary lower limb lymphedema: a mixed-methods study. West J Nurs Res. 2016;38:1313\u20131334. https:\/\/doi. org\/10.1177\/0193945916647961","DOI":"10.1177\/0193945916647961"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tDai M, Nakagami G, Sugama J, et al. The prevalence and functional impact of chronic edema and lymphedema in Japan: LIMPRINT study. Lymphat Res Biol. 2019;17:195\u2013201. https:\/\/doi.org\/10.1089\/lrb.2018.0080","DOI":"10.1089\/lrb.2018.0080"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tBowman C, Oberoi D, Radke L, Francis GJ, Carlson LE. Living with leg lymphedema: developing a novel model of quality lymphedema care for cancer survivors. J Cancer Surviv. 2021;15:140\u2013150. https:\/\/doi.org\/10.1007\/s11764-020- 00919-2","DOI":"10.1007\/s11764-020-00919-2"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tGuex JJ, Enriquez Vega DM, Avril L, Boussetta S, Ta\u00efeb C. Assessment of quality of life in Mexican patients suffering from chronic venous disorder \u2014 impact of oral Ruscus aculeatus\u2013hesperidin\u2013methyl-chalcone\u2013ascorbic acid treatment \u2014 \u2018QUALITY Study\u2019. Phlebology. 2009;24:157\u2013165. https:\/\/doi.org\/10.1258\/phleb.2009.008066","DOI":"10.1258\/phleb.2009.008066"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tZhou Y, Wang J, Yang W, et al. Bergapten prevents lipopolysaccharide-induced inflammation in RAW264.7 cells through suppressing JAK\/STAT activation and ROS production and increases the survival rate of mice after LPS challenge. Int Immunopharmacol. 2017;48:159\u2013168. https:\/\/doi.org\/10.1016\/j.intimp.2017.04.026","DOI":"10.1016\/j.intimp.2017.04.026"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tCastillo J, Benavente-Garc\u00eda O, Lorente J, et al. Antioxidant activity and radioprotective effects against chromosomal damage induced in vivo by X-rays of flavan-3-ols (procyanidins) from grape seeds (Vitis vinifera): comparative study versus other phenolic and organic compounds. J Agric Food Chem. 2000;48:1738\u201317345. https:\/\/doi.org\/10.1021\/jf990665o","DOI":"10.1021\/jf990665o"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tKiesewetter H, Koscielny J, Kalus U, et al. Efficacy of orally administered extract of red vine leaf AS 195 (Folia Vitis vinifera) in chronic venous insufficiency (stages I\u2013II). A randomized, double-blind, placebo-controlled trial. Arzneimittelforschung. 2000;50:109\u2013117. https:\/\/doi.org\/10.1055\/s-0031-1300174","DOI":"10.1055\/s-0031-1300174"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tSchaefer E, Peil H, Ambrosetti L, Petrini O. Oedema protective properties of the red vine leaf extract AS 195 (Folia Vitis vinifera) in the treatment of chronic venous insufficiency. A 6-week observational clinical trial. Arzneimittelforschung. 2003;53:243\u2013246. https:\/\/doi.org\/10.1055\/s-0031-1297103","DOI":"10.1055\/s-0031-1297103"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tRockson SG. Advances in lymphedema. Circ Res. 2021;128:2003\u20132016. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318307","DOI":"10.1161\/CIRCRESAHA.121.318307"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/02\/dic.2025-10-1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:19:21Z","timestamp":1791379161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/real-world-effectiveness-of-a-phlebotonic-formulation-combining-diosmin-ruscus-melilotus-and-vitis-vinifera-on-symptoms-and-quality-of-life-in-patients-with-chronic-venous-and-lymphatic-disease-res\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7573\/dic.2025-10-1","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"article-number":"dic.2025-10-1"}}